NEW YORK (TheStreet) -- German drugmaker Bayer said it would buy Merck's consumer care business, including brands like Claritin and Coppertone, for $14.2 billion.
German drugmaker Bayer said it would buy Merck's (MRK) consumer care business for $14.2 billion.The deal is set to make Bayer the second-biggest over-the-counter drug-maker behind Johnson & Johnson (JNJ). According to the company, it should add $2.2 billion in annual sales to its non-prescription business. Merck said it expects after-tax proceeds of between $8 billion and $9 billion from the deal. It said it plans to use the proceeds to develop products that have the highest potential growth opportunities. The deal is expected to close in the second half of 2014. It is the latest in a string of M&A activity within the drug space. Last month, Novartis (NVS), GlaxoSmithKline (GSK) and Eli Lilly (LLY) announced a $28.5 billion deal while Pfizer (PFE) has been seeking a $106 billion takeover of AstraZeneca (AZN). At last check, shares of Merck were falling about 1.7% to $57.64. In New York, I'm Brittany Umar for TheStreet. -- Written by Brittany Umar in New York.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV